Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-FC Induction and Rituximab Maintenance in First-Line CLL
NCT00545714Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2007
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), sponsored by Roche. Started Nov 2007; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00545714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00545714.